Eli Lilly reaffirms FY14 non-GAAP EPS; guides FY15 EPS towards low end of expectations, rev just below
Co reaffirms guidance for FY14 (Dec), sees EPS of $2.72-2.80, excluding non-recurring items, vs. $2.78 Capital IQ Consensus.
Co issues guidance for FY15 (Dec), sees EPS of $3.10-3.20, excluding non-recurring items, vs. $3.19 Capital IQ Consensus; sees FY15 (Dec) revs of $20.3-20.8 bln vs. $20.83 bln Capital IQ Consensus.
Co issues guidance for FY15 (Dec), sees EPS of $3.10-3.20, excluding non-recurring items, vs. $3.19 Capital IQ Consensus; sees FY15 (Dec) revs of $20.3-20.8 bln vs. $20.83 bln Capital IQ Consensus.
- The co expects to grow revenue with a first wave of product launches in diabetes, oncology and immunology followed by a second wave of potential launches in cardiovascular disease, Alzheimer's disease, pain and oncology. The company will focus on key geographies including the U.S., Japan, China and other select markets.
- Lilly will focus its internal research and development on the core areas of diabetes, oncology, neurodegeneration, immunology and pain. Lilly is also progressing with an ambitious effort to reduce significantly the development time required to bring new medicines to patients.
- The co aims to turn revenue growth into even greater earnings growth by controlling costs and leveraging existing infrastructure. By driving productivity improvements across the value chain, Lilly expects to reduce total operating expenses as a percent of revenue to 50% or less by the end of 2018.